Eight-Year Experience of Iodine-125 Monotherapy for Japanese Men With Localized Prostate Cancer

Abstract

98% of the patients received ADT, for a median duration of 6 months. Endpoints of investigation included biochemical relapse free survival (bRFS) using nadir PSA + 2 ng/mL definition of relapse, distant metastases free survival (DMFS), overall survival (OS), and prostate cancer specific mortality (PCSM). Results: Comparative statistical analyses between the two groups were performed using chi-square tests. Kaplan-Meier analyses were used to describe bRFS, DMFS, and OS, and cumulative incidence was used to report PCSM. At a median follow-up of 5.75 years, no statistically significant differences were found between patients with any Gleason pattern 5 versus other high-risk disease features in terms of bRFS, DMFS, OS, or PCSM. Conclusions: In our analysis of a high-risk prostate cancer population treated with high-dose EBRT and ADT, any Gleason pattern 5 did not bode for worse outcomes when compared to other high-risk patients. This finding counters recently reported series that suggest worse DMFS and OS in patients with Gleason pattern 5 components. The implication of Gleason pattern 5, while provocative, is yet to be proven prospectively. Author Disclosure: G. Marwaha: None. C. Reddy: None. M.A. Weller: None. R. Kotecha: None. J.W.D. Hearn: None. J.P. Ciezki: None. K.L. Stephans: None. R.D. Tendulkar: None.